Monitor the November 30, 2026 deadline for the definitive agreement with PsyLabs and any DEA actions on import permits or quota expansions. The partnership is a necessary but non-revenue-generating infrastructure step; without clinical trial initiation or regulatory milestones, the stock remains a speculative pre-revenue story dependent on continued equity line financing.
Price Chart
Executive Summary
Psyence Biomedical's wholly-owned Texas subsidiary, TIRC, entered a manufacturing services agreement with DEA-registered Benuvia Operations to establish U.S.-based cGMP production of pharmaceutical-grade ibogaine API. The partnership connects TIRC's planned exclusive U.S. access to PsyLabs' ibogaine with Benuvia's existing DEA-registered facility and approximately half of the U.S. aggregate production quota for ibogaine. While this is a structural step toward an integrated U.S. supply chain, the company remains pre-revenue with no approved products, and the pathway to revenue depends on future DEA quota expansions, regulatory approvals, and conclusion of a definitive agreement with PsyLabs by November 30, 2026.
Key Facts
- TIRC entered a manufacturing services agreement with Benuvia Operations, LLC for planned U.S. manufacture of pharmaceutical-grade ibogaine API under cGMP standards.
- Benuvia operates an 83,000-square-foot DEA-registered controlled-substance manufacturing facility in Round Rock, Texas.
- Benuvia currently holds approximately half of the U.S. aggregate production quota for ibogaine.
- The partnership builds on TIRC's binding term sheet with PsyLabs for exclusive U.S. license, supply and wholesale distribution of pharmaceutical-grade ibogaine; definitive agreement due by November 30, 2026.
- Applications for import permit and procurement quota are being advanced with the DEA by Benuvia.
- The company remains pre-revenue with no FDA-approved products; ibogaine is a DEA Schedule I controlled substance with no established safety or efficacy through authorized clinical research.
- Per the prior 20-F (filed June 2026), the company reported a net loss of $6.89 million for FY2026, cash of $7.49 million, and reliance on a dilutive $100M White Lion equity line.
Financial Impact
No financial terms of the manufacturing agreement were disclosed. The company remains pre-revenue with no near-term revenue catalyst.
Risk Factors
- Definitive agreement with PsyLabs may not be concluded by November 30, 2026, or at all.
- DEA import permits, procurement quotas, and other regulatory authorizations may be delayed, limited, or refused.
- Ibogaine remains a DEA Schedule I controlled substance with no FDA approval; clinical trials have not commenced.
- Reliance on a single manufacturing partner (Benuvia) and a single related-party supplier (PsyLabs) creates concentration risk.
- The company continues to rely on a dilutive $100M White Lion equity line to fund operations, with $16.9M drawn post-FY2026 year-end.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-106630 |
| Document: ea0307592-6k_psyence.htm | 0001213900-26-106630 |
| Document: 0001213900-26-106630-index-headers.html | 0001213900-26-106630 |
| Document: 0001213900-26-106630-index.html | 0001213900-26-106630 |
| Document: 0001213900-26-106630.txt | 0001213900-26-106630 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $4.52 $4.12 | ▼ −8.85% | ▼ −7.67% | $4.03 (−10.81%) |
Oct 15, 2026 11d ago | SC 13D/A | $4.32 $4.22 | ▼ −2.31% | ▼ −1.21% | $4.03 (−6.68%) |
Oct 5, 2026 21d ago | SC 13G | $5.08 $5.02 | ▼ −1.18% | ▼ −1.73% | $4.03 (−20.64%) |
Oct 5, 2026 21d ago | 6-K | $5.08 $5.02 | ▼ −1.18% | ▼ −1.73% | $4.03 (−20.64%) |
Oct 5, 2026 21d ago | Press Release | $5.08 $5.02 | ▼ −1.18% | ▼ −1.73% | $4.03 (−20.64%) |
Sep 28, 2026 28d ago | 6-K | $5.67 $5.43 | ▼ −4.15% | ▼ −3.96% | $4.03 (−28.84%) |
Sep 28, 2026 28d ago | Press Release | $5.67 $5.43 | ▼ −4.15% | ▼ −3.96% | $4.03 (−28.84%) |
Sep 23, 2026 4w ago | 6-K | $6.31 $5.86 | ▲ +7.13% | ▲ +7.05% | $4.03 (+36.11%) |
Sep 14, 2026 6w ago | 6-K | $6.00 $6.07 | ▲ +1.17% | ▲ +1.63% | $4.03 (−32.81%) |
Sep 2, 2026 7w ago | EFFECT | $4.37 $4.43 | ▲ +1.37% | ▲ +0.33% | $4.03 (−7.75%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers